Craniotomy for Cerebral Aneurysm Clipping — Cost, Top Hospitals & Success Rates | MyMedicPlus

Craniectomy for intracranial aneurysms and arteriovenous malformations (AVMs) encompasses the neurosurgical cranial approaches required to surgically treat these vascular abnormalities of the brain. An intracranial aneurysm is a focal saccular dilation of a cerebral artery wall — typically at bifurcation points in the Circle of Willis — resulting from degeneration of the arterial media and internal elastic lamina. Unruptured aneurysms are discovered incidentally on neuroimaging in approximately 3-5% of the general population. Aneurysm rupture causes subarachnoid haemorrhage (SAH) — bleeding into the cerebrospinal fluid space surrounding the brain — with catastrophic neurological consequences: 30-day mortality approaching 45%, and significant neurological disability in survivors.

Surgical treatment of intracranial aneurysms through a craniotomy (or craniectomy when brain swelling requires decompression) involves direct microsurgical access to the aneurysm through a skull opening, typically via a pterional (frontotemporal) approach for anterior circulation aneurysms, a retrosigmoid or far-lateral approach for posterior fossa aneurysms, or an interhemispheric approach for anterior communicating artery aneurysms. Using an operating microscope and microsurgical techniques, the neurosurgeon dissects the brain tissue planes, identifies the aneurysm neck, and places a titanium clip across the aneurysm neck to permanently exclude it from the circulation while preserving the parent and branch arteries. The term 'AXM' in this context may refer to an aneurysm craniectomy procedure where extensive brain swelling (from subarachnoid haemorrhage-associated vasospasm or the haemorrhage itself) necessitates craniectomy rather than craniotomy with bone flap replacement.

Cerebral arteriovenous malformations (AVMs) are congenital tangles of abnormal arteries and veins without intervening capillaries — the thin-walled AVM vessels carry high arterial pressure directly without the normal pressure-reducing capillary bed, predisposing to haemorrhage (risk 2-4% per year), seizures, headaches, and progressive neurological deficits. Surgical resection of AVMs through craniotomy remains the definitive curative treatment for accessible superficial AVMs, though endovascular embolisation and stereotactic radiosurgery (Gamma Knife) are increasingly used as adjuncts or alternatives depending on AVM grade.

Surgical craniectomy/craniotomy for aneurysms is indicated for: ruptured intracranial aneurysms causing subarachnoid haemorrhage (surgical or endovascular intervention within 24-72 hours to prevent rebleeding — rebleeding carries 70% mortality without treatment); unruptured aneurysms deemed to be at significant rupture risk (size >7 mm, irregular morphology, specific locations, growth on serial imaging, patient age, and aneurysm characteristics per PHASES score); giant aneurysms (>25 mm) not suitable for endovascular coiling; complex-shaped or broad-necked aneurysms where clip reconstruction achieves better long-term durability than coiling; and aneurysms associated with intracerebral haematoma requiring surgical evacuation.

AVM surgery is considered for Spetzler-Martin Grade I-III AVMs (accessible, small, in non-eloquent cortex with superficial venous drainage) where surgical cure rates exceed 95% with acceptable risk. Higher-grade AVMs (Grade IV-V) are managed with multimodality treatment combining embolisation, radiosurgery, or observation. AVMs presenting with haemorrhage, intractable seizures, or progressive neurological deficits have stronger surgical indications than asymptomatic AVMs.

Eligibility for surgical aneurysm treatment involves weighing the procedural risk against the natural history risk of the aneurysm. Patient factors include neurological status (Hunt and Hess grade for SAH patients — grades I-III have better outcomes than grades IV-V), age, medical comorbidities, anatomical accessibility of the aneurysm, and aneurysm characteristics. For ruptured aneurysms, the benefit of preventing rebleeding generally outweighs procedural risk for most patients with acceptable neurological grade. For unruptured aneurysms, the PHASES score, UIATS, and institutional guidelines help quantify rupture risk to guide treatment decisions.

Contraindications to surgical clipping include Hunt and Hess Grade V SAH (moribund patients where surgical benefit is negligible), significant systemic medical illness precluding safe general anaesthesia, and deeply located eloquent cortex AVMs where surgery would produce unacceptable neurological deficit. For these situations, endovascular coiling (for aneurysms) or radiosurgery (for AVMs) may be preferred alternatives.

Microsurgical aneurysm clipping through craniotomy involves a precisely planned skull opening, dural incision, careful microsurgical dissection of basal cisterns and sylvian fissure to reach the aneurysm, temporary clipping of the parent artery to soften the aneurysm for safe dissection, permanent titanium clip application across the aneurysm neck, and intraoperative angiography or indocyanine green (ICG) video angiography to confirm complete aneurysm occlusion and parent artery patency before wound closure. Intraoperative neuromonitoring (SSEPs, MEPs, EEG) guides safe dissection in functionally critical areas.

Endovascular coiling (endovascular treatment — EVT) — the major alternative to surgical clipping — involves navigating a microcatheter via the femoral artery through the aorta, carotid arteries, and cerebral vessels into the aneurysm sac, then deploying platinum microcoils to fill the aneurysm and promote thrombosis. The International Subarachnoid Aneurysm Trial (ISAT) and ISAT 10-year follow-up demonstrated superior early outcomes for coiling versus clipping for aneurysms technically suitable for either approach, with higher 1-year rates of independence in coiled patients. However, clip obliteration rates are higher than coiling, and complex or broad-necked aneurysms often require surgical clipping for complete, durable exclusion. Intraoperative aneurysm rupture — occurring in 5-10% of surgical clipping cases — is managed by rapid temporary clipping of the parent artery proximal and distal to the aneurysm while the ruptured dome is repaired, requiring the surgeon to have pre-planned access to proximal vascular control before approaching the aneurysm dome.

Surgical clipping achieves complete and durable aneurysm occlusion in 97-99% of cases, with very low recurrence rates (<1-2% at long-term follow-up) — significantly superior to coiling (recanalisation requiring repeat treatment in 15-20% at 5 years). For ruptured aneurysms, timely surgical or endovascular treatment prevents the catastrophic rebleeding that occurs in 20-30% of untreated aneurysms within 2 weeks of the initial rupture, with 70-80% mortality from rebleed events.

For AVM surgery, Spetzler-Martin Grade I-II AVM resection achieves complete obliteration (cure) in >95% of cases with acceptable morbidity. AVM cure eliminates the ongoing annual haemorrhage risk of 2-4% per year for life, which in young patients with a normal life expectancy translates to a cumulative lifetime haemorrhage risk of 30-60%. Seizure freedom rates of 70-85% are reported after AVM surgery in patients presenting with seizure. The benefit of surgery is greatest in young patients with low-grade AVMs in accessible locations.

Intraoperative aneurysm rupture during surgical dissection is the most feared complication, occurring in 10-20% of cases (controlled with temporary clipping and rapid clip application). Perforator artery or branch artery occlusion during clip placement causes ischaemic stroke in the territory of the affected artery — a risk varying by aneurysm location. Post-operative cerebral vasospasm (symptomatic in ~30% of SAH patients, 2-14 days post-SAH) causes delayed ischaemic neurological deficits managed with calcium channel blockers (nimodipine), induced hypertension, and endovascular vasodilation.

Hydrocephalus develops in 15-20% of SAH patients from blood interfering with CSF absorption, requiring external ventricular drain (EVD) acutely and ventriculoperitoneal shunt in approximately 20-30% of SAH survivors. General surgical risks include wound infection, meningitis, cerebral oedema, haematoma at the operative site, and DVT/PE. For AVM surgery, post-operative normal perfusion pressure breakthrough haemorrhage (NPPB) — a rare but serious complication caused by sudden hyperperfusion in chronically ischaemic surrounding brain after AVM removal — requires careful perioperative blood pressure management.

Post-operative management of SAH patients in the neurocritical care unit involves: ICP monitoring, nimodipine for vasospasm prevention, transcranial Doppler monitoring for vasospasm, euvolaemia and normalisation of sodium (hyponatraemia is common post-SAH), seizure prophylaxis, and daily neurological assessment. DSA (digital subtraction angiography) or CTA at 3-6 months post-clipping confirms complete aneurysm occlusion and parent artery patency. Annual or 3-yearly MRA or CTA surveillance monitors for recurrence of clipped aneurysms and detection of new aneurysms (risk of de novo aneurysm formation: 1-2% per year in the same patient).

Neurological rehabilitation following SAH and aneurysm surgery begins as soon as the patient is medically stable and continues for months to years. Cognitive rehabilitation (for memory, attention, executive function deficits — common SAH sequelae), physiotherapy (for motor deficits), speech therapy (aphasia after dominant hemisphere aneurysm), and psychological support (post-SAH anxiety and depression affect 25-50% of survivors) are integral to comprehensive neurorehabilitation. Return to work timelines vary widely by cognitive and physical recovery and occupational demands.

Ruptured aneurysm treatment is an emergency covered by health systems and insurance globally. In the USA, SAH hospitalisation and aneurysm treatment costs USD 75,000-200,000 depending on complexity and ICU duration; rehabilitation adds substantially. NHS in the UK covers all emergency aneurysm treatment. For unruptured aneurysm treatment, costs are lower but still significant: USD 25,000-60,000 for surgical clipping in the USA; GBP 10,000-20,000 in private UK care.

India's top neurosurgical centres — NIMHANS (Bengaluru), AIIMS (Delhi), Apollo, Fortis, and Kokilaben Dhirubhai Ambani Hospital — offer microsurgical aneurysm clipping and AVM surgery by internationally trained neurosurgeons at 40-60% of US private rates. AVM radiosurgery using Gamma Knife or CyberKnife is available at multiple accredited centres in India and Thailand at significantly lower cost than Western centres. Medical tourism for elective unruptured aneurysm treatment to these destinations is a growing sector.

Endovascular coiling — navigating microcatheters to the aneurysm and filling it with platinum coils — is the primary alternative to surgical clipping. ISAT trial evidence supports coiling over clipping for aneurysms technically suitable for both, particularly in older patients and those with posterior circulation aneurysms (basilar tip, PCA). Flow diverters (Pipeline Embolization Device — PED) placed in the parent artery to redirect blood flow away from the aneurysm and promote sac thrombosis are used for large, wide-necked, or fusiform aneurysms not suitable for coiling or clipping.

For AVMs, endovascular embolisation (partial treatment that reduces AVM volume before surgery or radiosurgery) and stereotactic radiosurgery (Gamma Knife, CyberKnife, Linac) delivering focused radiation to destroy AVM vessels over 2-3 years are established non-surgical alternatives. Radiosurgery achieves obliteration in 70-85% of small AVMs (diameter <3 cm) at 3 years after treatment, with recurrent haemorrhage risk persisting during the treatment latency period. For unruptured AVMs, conservative management (observation without treatment) is supported by the ARUBA trial, which found medical management superior to interventional treatment for unruptured brain AVMs over 5 years — though this remains controversial for younger patients with accessible low-grade AVMs.